Aduro Becomes Latest Immuno-Oncology Biotech To Plan IPO
Pancreatic cancer immunotherapy developer Aduro Biotech Inc. is eyeing an $86.25 million initial public offering, according to a regulatory filing on Wednesday, riding a wave of immuno-oncology biotechs tapping the public...To view the full article, register now.
Already a subscriber? Click here to view full article